問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Fu Jen Catholic University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 243New Taipei CityTaishan

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

12Cases

2024-08-01 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2024-10-30 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-12-01 - 2026-12-31

Phase I/II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
3Sites

Recruiting3Sites

2022-04-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-02-27 - 2030-01-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Suspended15Sites

2024-02-26 - 2026-07-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

2023-01-16 - 2025-08-30

Phase III

Active
A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke

  • Test Drug

    asundexianPlacebo

Participate Sites
23Sites

Not yet recruiting6Sites

Recruiting17Sites

2023-02-01 - 2028-01-31

Phase II

Active
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of ADI-PEG 20 or Placebo in Subjects With Nonalcoholic Steatohepatitis (NASH)

  • Condition/Disease

    Nonalcoholic Steatohepatitis (NASH)

  • Test Drug

    ADI-PEG 20

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2023-12-01 - 2026-12-31

Phase I

An Open-Label, Non-Randomized, Dose-Escalation Phase I Study to Evaluate the Safety of UA002 (Allogeneic Amniotic Fluid Stem Cells) in Subjects with Diabetes Mellitus (DM)- or Radical Prostatectomy (RP)-Associated Erectile Dysfunction (ED)

  • Condition/Disease

    Erectile Dysfunction (ED)

  • Test Drug

    UA002

Participate Sites
2Sites

Not yet recruiting2Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB